Rare disease pharmacy solutions specialist Orsini announced on Tuesday that it has partnered with PicnicHealth, a health technology company focused on simplifying observational research.

This collaboration is intended to enable rapid development of drug-specific registries that combine real world drug data, curated electronic medical records (EMR) and patient-reported perspectives. The result is more comprehensive real-world data on approved therapies, providing deeper insights into patient treatment journeys and medication adherence to improve care for rare disease patients.

In 2024, PicnicHealth launched its life sciences research product to simplify observational research and enable life sciences companies to meet study endpoints. Orsini recently introduced ORBIT (Orsini Rare Business Intelligence Technology), an AI-powered reporting and analytics platform designed to enhance care for rare disease patients. The two companies, by integrating their expertise, aim to generate meaningful insights on patient adherence and long-term results, driving the success of specialised therapies within rare disease populations.

To launch this venture, the partners are collaborating with biopharmaceutical company AstraZeneca to gather insights on WAINUA (eplontersen). Orsini is the exclusive specialty pharmacy partner for WAINUA, an FDA-approved treatment for adults living with hereditary transthyretin-mediated amyloid polyneuropathy (commonly referred to as hATTR-PN or ATTRv-PN).

Brandon Tom, Orsini's CEO, said: "We are thrilled to partner with PicnicHealth to gain a deeper understanding of patient adherence through real-world data and to work with AstraZeneca to bring these powerful insights to hATTR-PN patients. Adherence is a critical factor to help ensure successful patient outcomes, particularly in rare disease communities. This partnership is another step forward in our mission to leave no patient behind."